All In Biotech

Drug Trial Radar · NCT05597280

Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy

Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 3 Study

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 124,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

124,000

Planned (sponsor's estimate)

Start

Mar 22, 2023

Primary completion

Mar 15, 2027

Study completion Mar 15, 2027

Sponsor

Lead sponsor
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

There will be two study arms. Arm 1 will be the intervention arm in which there will be provided BE-PEP to all persons residing within 100 meters of an index case, to be repeated after four weeks for household contacts. Arm 2 will be the comparator arm in which the WHO recommended standard PEP will be provided, i.e. 10 mg/kg of rifampicin in a single dose. In both arms the investigators will target anyone living within 100 meters of an index case or the entire village if more than 50% are eligible. Provision of BE-PEP will start in 2023 and follow-up will continue until 2026. The main study outcome will be the comparison of leprosy risk in individuals that received BE-PEOPLE standard WHO SDR-PEP versus individuals that received BE-PEP. In addition the investigators will compare the overall leprosy incidence over the follow-up period between the two study arms.

Conditions

  • Leprosy

Interventions

  • BE-PEP BedaquilineDrug

    bedaquiline

  • SDR-PEP RifampicinDrug

    SDR-PEP: rifampicin

  • BE-PEP RifampicinDrug

    BE-PEP rifampicin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate effectiveness of PEP based on a combination of rifampicin and bedaquiline (BE-PEP), in preventing leprosy among contacts of incident cases.Time frame: Through study completion, an average of 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fondation Damien

    Moroni, Comoros · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.